JP2020505044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505044A5 JP2020505044A5 JP2019540095A JP2019540095A JP2020505044A5 JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5 JP 2019540095 A JP2019540095 A JP 2019540095A JP 2019540095 A JP2019540095 A JP 2019540095A JP 2020505044 A5 JP2020505044 A5 JP 2020505044A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- genetically modified
- protein
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 108700019146 Transgenes Proteins 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000002950 deficient Effects 0.000 claims description 8
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 4
- 108010076282 Factor IX Proteins 0.000 claims description 4
- 208000031220 Hemophilia Diseases 0.000 claims description 4
- 208000009292 Hemophilia A Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 229960004222 factor ix Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108091008875 B cell receptors Proteins 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000634835 Homo sapiens M1-specific T cell receptor alpha chain Proteins 0.000 claims description 2
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 2
- 101000634836 Homo sapiens T cell receptor alpha chain MC.7.G5 Proteins 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 2
- 230000006023 anti-tumor response Effects 0.000 claims description 2
- 230000005875 antibody response Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 230000008614 cellular interaction Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000012239 gene modification Methods 0.000 claims description 2
- 230000005017 genetic modification Effects 0.000 claims description 2
- 235000013617 genetically modified food Nutrition 0.000 claims description 2
- 210000001280 germinal center Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 210000002707 regulatory b cell Anatomy 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173206A JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450917P | 2017-01-26 | 2017-01-26 | |
| US62/450,917 | 2017-01-26 | ||
| PCT/US2018/015180 WO2018140573A1 (en) | 2017-01-26 | 2018-01-25 | B-cell engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Division JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505044A JP2020505044A (ja) | 2020-02-20 |
| JP2020505044A5 true JP2020505044A5 (enExample) | 2020-12-17 |
Family
ID=62979713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540095A Withdrawn JP2020505044A (ja) | 2017-01-26 | 2018-01-25 | Ｂ細胞操作 |
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173206A Pending JP2022191524A (ja) | 2017-01-26 | 2022-10-28 | Ｂ細胞操作 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190352614A1 (enExample) |
| EP (1) | EP3573464A4 (enExample) |
| JP (2) | JP2020505044A (enExample) |
| KR (1) | KR20190111063A (enExample) |
| CN (1) | CN110536963A (enExample) |
| AU (1) | AU2018212652B2 (enExample) |
| BR (1) | BR112019015355A2 (enExample) |
| CA (1) | CA3051113A1 (enExample) |
| IL (1) | IL268110B2 (enExample) |
| MX (1) | MX2019008844A (enExample) |
| WO (1) | WO2018140573A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| BR112019015355A2 (pt) * | 2017-01-26 | 2020-05-19 | Sangamo Therapeutics Inc | modificação genética de células b |
| EP3595681A4 (en) * | 2017-03-16 | 2020-12-16 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| SG11202103734PA (en) | 2018-10-18 | 2021-05-28 | Intellia Therapeutics Inc | Compositions and methods for expressing factor ix |
| US20220403002A1 (en) * | 2019-11-01 | 2022-12-22 | Kyoto Prefectural Public University Corporation | B-cell antibody receptor and use thereof |
| EP4127188A4 (en) | 2020-03-31 | 2024-08-21 | Walking Fish Therapeutics | MODIFIED B CELLS AND METHODS OF USE THEREOF |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| WO2024151683A2 (en) * | 2023-01-09 | 2024-07-18 | Walking Fish Therapeutics, Inc. | HUMAN B CELL ENGINEERED TO EXPRESS IgA AND IgM ANTIBODIES FOR THERAPEUTIC USE |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
| WO2024220447A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of niemann pick b disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901511A0 (en) * | 2003-03-28 | 2003-04-17 | Bionomics Limited | Nucleic acid molecules associated with angiogenesis II |
| EP2438931B1 (en) * | 2004-09-22 | 2013-11-13 | St. Jude Children's Research Hospital | Improved expression of factor IX in gene therapy vectors |
| WO2010117464A1 (en) * | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
| WO2014186585A2 (en) * | 2013-05-15 | 2014-11-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US9757420B2 (en) * | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
| JP6722176B2 (ja) * | 2014-09-16 | 2020-07-15 | サンガモ セラピューティクス， インコーポレイテッド | 造血幹細胞におけるヌクレアーゼ媒介性ゲノム工学および補正のための方法および組成物 |
| DK3234107T3 (da) * | 2014-12-19 | 2022-10-17 | Immusoft Corp | B-celler til in vivo-levering af terapeutiske midler |
| CA2981077A1 (en) * | 2015-04-03 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| CA2990620A1 (en) * | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
| EP3322297B1 (en) * | 2015-07-13 | 2024-12-04 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| KR20180127319A (ko) * | 2016-01-15 | 2018-11-28 | 상가모 테라퓨틱스, 인코포레이티드 | 신경 질환의 치료를 위한 방법 및 조성물 |
| BR112019015355A2 (pt) * | 2017-01-26 | 2020-05-19 | Sangamo Therapeutics Inc | modificação genética de células b |
| CA3059645A1 (en) * | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| KR102708624B1 (ko) * | 2017-06-16 | 2024-09-20 | 상가모 테라퓨틱스, 인코포레이티드 | T 세포 및/또는 hla 수용체의 표적화된 파괴 |
| EP3665271A4 (en) * | 2017-08-08 | 2021-04-28 | Sangamo Therapeutics, Inc. | CELL TARGETING MEDIA BY A CHEMICAL ANTIGEN RECEPTOR |
| SG11202004003YA (en) * | 2017-11-09 | 2020-05-28 | Sangamo Therapeutics Inc | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
| EP3694546A1 (en) * | 2018-01-30 | 2020-08-19 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen |
| EP3844282A4 (en) * | 2018-08-29 | 2022-06-01 | Nanjing Legend Biotech Co., Ltd. | ANTI-MESOTHELIN CHIMERAL ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND THEIR USES |
| EP3887395A4 (en) * | 2018-11-30 | 2022-07-27 | Intima Bioscience, Inc. | METHODS FOR IDENTIFICATION OF IMMUNOMODULATORY GENES |
-
2018
- 2018-01-25 BR BR112019015355A patent/BR112019015355A2/pt not_active IP Right Cessation
- 2018-01-25 KR KR1020197023790A patent/KR20190111063A/ko not_active Ceased
- 2018-01-25 MX MX2019008844A patent/MX2019008844A/es unknown
- 2018-01-25 US US16/480,939 patent/US20190352614A1/en not_active Abandoned
- 2018-01-25 AU AU2018212652A patent/AU2018212652B2/en not_active Ceased
- 2018-01-25 JP JP2019540095A patent/JP2020505044A/ja not_active Withdrawn
- 2018-01-25 CA CA3051113A patent/CA3051113A1/en active Pending
- 2018-01-25 WO PCT/US2018/015180 patent/WO2018140573A1/en not_active Ceased
- 2018-01-25 CN CN201880021264.1A patent/CN110536963A/zh active Pending
- 2018-01-25 EP EP18744407.0A patent/EP3573464A4/en active Pending
- 2018-01-25 IL IL268110A patent/IL268110B2/en unknown
-
2022
- 2022-10-28 JP JP2022173206A patent/JP2022191524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505044A5 (enExample) | ||
| JP2017500061A5 (enExample) | ||
| Kumar et al. | Clinical development of gene therapy: results and lessons from recent successes | |
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| JP2020500162A5 (enExample) | ||
| Wolf et al. | Beyond vascular inflammation—recent advances in understanding atherosclerosis | |
| JP2016539627A5 (enExample) | ||
| De Ciuceis et al. | Immune mechanisms in hypertension | |
| Kohn | Gene therapy for blood diseases | |
| JP2017504354A5 (enExample) | ||
| JP2021505187A (ja) | 遺伝子編集のためのｃｐｆ１関連方法及び組成物 | |
| Naeimi Kararoudi et al. | Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation | |
| Paladini et al. | The multifaceted nature of aminopeptidases ERAP1, ERAP2, and LNPEP: from evolution to disease | |
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| Ly et al. | Gene therapy in the treatment of heart failure | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| Crossley et al. | Effective therapies for sickle cell disease: are we there yet? | |
| Bottino et al. | Use of genetically-engineered pig donors in islet transplantation | |
| Hodge et al. | Wide awake and ready to move: 20 years of non-viral therapeutic genome engineering with the sleeping beauty transposon system | |
| Wilcox | Megakaryocyte-and megakaryocyte precursor–related gene therapies | |
| Lidonnici et al. | Gene therapy for hemoglobinopathies | |
| Naldini et al. | The EHA research roadmap: hematopoietic stem cell gene therapy | |
| Wu et al. | Multiple gene modifications of pigs for overcoming obstacles of xenotransplantation | |
| Sii-Felice et al. | Innovative therapies for hemoglobin disorders |